Braftovi (encorafenib) vs Zynyz (retifanlimab-dlwr)

Braftovi (encorafenib) is a targeted therapy known as a BRAF inhibitor, specifically used for the treatment of melanoma with a BRAF V600E or V600K mutation, often in combination with other medications. Zynyz (retifanlimab-dlwr), on the other hand, is an immune checkpoint inhibitor that targets the PD-1/PD-L1 pathway and is used in the treatment of advanced or metastatic solid tumors in patients who have limited treatment options. The choice between Braftovi and Zynyz would depend on the type of cancer, its molecular profile, and the patient's overall health status, which should be evaluated by a healthcare professional to determine the most appropriate treatment option.

Difference between Braftovi and Zynyz

Metric	Braftovi (encorafenib)	Zynyz (retifanlimab-dlwr)
Generic name	Encorafenib	Retifanlimab-dlwr
Indications	Used in the treatment of metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test, and in combination with a MEK inhibitor for the treatment of metastatic colorectal cancer with a BRAF V600E mutation.	Indicated for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum-based chemotherapy.
Mechanism of action	A BRAF inhibitor, it works by selectively targeting and inhibiting a mutated form of the BRAF protein found in some cancer cells.	A PD-1 blocking antibody, it works by enhancing the body’s immune response against cancer cells by inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Brand names	Braftovi	Zynyz
Administrative route	Oral	Intravenous
Side effects	Most common side effects include fatigue, nausea, diarrhea, vomiting, abdominal pain, and arthralgia.	Common side effects include anemia, asthenia, constipation, decreased appetite, diarrhea, fatigue, fever, and abdominal pain.
Contraindications	Should not be used in patients with known hypersensitivity to encorafenib or any of its excipients.	Should not be used in patients with a history of severe hypersensitivity reaction to retifanlimab or any of its excipients.
Drug class	Kinase inhibitor	Immune checkpoint inhibitor
Manufacturer	Pfizer	Inc. (as of the knowledge cutoff date)

Efficacy

Efficacy of Braftovi (Encorafenib) in Skin Cancer Treatment

Braftovi, also known by its generic name encorafenib, is a medication specifically approved for the treatment of certain types of skin cancer. Its efficacy is primarily observed in patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test. Encorafenib, a BRAF inhibitor, is designed to target and inhibit the activity of the mutated BRAF protein, which can lead to cancer cell growth. When used in combination with binimetinib, a MEK inhibitor, Braftovi has demonstrated a significant improvement in progression-free survival compared to BRAF inhibitor monotherapy. Clinical trials have shown that this combination therapy can delay the progression of the disease and, in some cases, reduce the size of the tumors.

Efficacy of Zynyz (Retifanlimab-dlwr) in Skin Cancer Treatment

Zynyz, with the generic name retifanlimab-dlwr, is an investigational drug and its efficacy in skin cancer treatment is still being evaluated in clinical trials. Retifanlimab is a type of immunotherapy known as a checkpoint inhibitor, which works by targeting the PD-1/PD-L1 pathway, a mechanism that tumors use to evade the immune system. By blocking this pathway, retifanlimab aims to restore the immune system's ability to recognize and destroy cancer cells. However, as of the knowledge cutoff date, retifanlimab-dlwr has not been approved by the FDA for the treatment of skin cancer, and its efficacy for this indication is not yet established. Ongoing clinical studies are necessary to determine its safety and effectiveness in patients with skin cancer.

It is important for patients to consult with their healthcare providers to understand the potential benefits and risks of these treatments and to determine if they are appropriate candidates for therapy with Braftovi or investigational drugs like Zynyz. Personalized treatment plans based on the specific type and stage of skin cancer, as well as the patient's overall health and genetic makeup, are crucial for achieving the best possible outcomes.

Patients should also be aware that the efficacy of cancer treatments can vary widely among individuals, and that continued research and clinical trials are essential for advancing the understanding and management of skin cancer. Healthcare providers will rely on the most current research data and clinical guidelines to make informed treatment recommendations for their patients.

Regulatory Agency Approvals

Braftovi

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Zynyz

Food and Drug Administration (FDA), USA

Access Braftovi or Zynyz today

If Braftovi or Zynyz are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Braftovi

Buy Zynyz

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: